FIL Ltd Has $43.66 Million Stock Position in Heron Therapeutics Inc (NASDAQ:HRTX)

FIL Ltd lessened its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 21.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,786,308 shares of the biotechnology company’s stock after selling 481,546 shares during the quarter. FIL Ltd owned 2.26% of Heron Therapeutics worth $43,658,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Parallel Advisors LLC increased its stake in Heron Therapeutics by 247.4% during the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock worth $41,000 after buying an additional 1,200 shares in the last quarter. Pearl River Capital LLC grew its position in shares of Heron Therapeutics by 1,900.0% in the first quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Heron Therapeutics by 24.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Heron Therapeutics in the first quarter valued at approximately $151,000. Finally, Stephens Inc. AR purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $208,000.

Heron Therapeutics stock traded up $0.35 during midday trading on Monday, reaching $18.94. The company’s stock had a trading volume of 819,600 shares, compared to its average volume of 1,028,110. The stock’s 50-day moving average is $17.92. The stock has a market cap of $1.47 billion, a P/E ratio of -7.76 and a beta of 1.59. Heron Therapeutics Inc has a fifty-two week low of $16.20 and a fifty-two week high of $41.55. The company has a current ratio of 4.40, a quick ratio of 4.06 and a debt-to-equity ratio of 0.04.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.30). The company had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The business’s quarterly revenue was up 172.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.09) EPS. As a group, equities research analysts forecast that Heron Therapeutics Inc will post -2.66 earnings per share for the current year.

In related news, Director Waage Christian acquired 1,400 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the transaction, the director now directly owns 1,400 shares of the company’s stock, valued at approximately $25,256. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John Poyhonen acquired 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were bought at an average price of $17.55 per share, with a total value of $52,650.00. Following the completion of the transaction, the director now directly owns 13,000 shares in the company, valued at $228,150. The disclosure for this purchase can be found here. 12.56% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on HRTX shares. Northland Securities set a $55.00 price target on Heron Therapeutics and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. Cantor Fitzgerald lowered Heron Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, March 4th. BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $48.20.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: What Are Treasury Bonds?

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.